髓系细胞触发受体2（TREM2）在急慢性肝病中的作用

崔馨月; 孙全昊; 郑丽红; 王海强

doi:10.12449/JCH250228

髓系细胞触发受体2（TREM2）在急慢性肝病中的作用

DOI: 10.12449/JCH250228

1.
黑龙江中医药大学第一临床医学院，哈尔滨 150040
2.
黑龙江中医药大学附属第四医院消化内科，哈尔滨 150001
3.
黑龙江中医药大学附属第一医院消化二科，哈尔滨 150040

基金项目:

国家中医药管理局第五批全国中医临床优秀人才研修项目 (the State Administration of Traditional Chinese Medicine Human Education Letter ［2022］ No.1);

黑龙江中医药大学“优秀青年骨干教师”计划 (15041190018)

利益冲突声明：本文不存在任何利益冲突。

作者贡献声明：崔馨月负责文章的构思与设计，论文撰写；孙全昊负责论文修订；郑丽红负责论文修订与审校；王海强负责最终版本修订。

详细信息

通信作者:
王海强， haiqiang915@163.com （ORCID： 0000-0002-1183-0283）

计量
- 文章访问数: 95
- HTML全文浏览量: 62
- PDF下载量: 9
- 被引次数: 0
出版历程
- 收稿日期: 2024-06-03
- 录用日期: 2024-06-20
- 出版日期: 2025-02-25

Role of triggering receptor expressed on myeloid cells 2 in acute and chronic liver diseases

1.
The First Clinical College of Heilongjiang University of Chinese Medicine，Harbin 150040，China
2.
Department of Gastroenterology，The Fourth Affiliated Hospital of Heilongjiang University of Chinese Medicine，Harbin 150001，China
3.
Second Department of Gastroenterology，The First Affiliated Hospital of Heilongjiang University of Chinese Medicine，Harbin 150040，China

Research funding:

State Administration of Traditional Chinese Medicine, the Fifth Batch of National Chinese Medicine Clinical Excellence Training Program (the State Administration of Traditional Chinese Medicine Human Education Letter ［2022］ No.1);

Heilongjiang University of Traditional Chinese Medicine “Outstanding Young Backbone Teachers” Program (15041190018)

More Information

Corresponding author: WANG Haiqiang， haiqiang915@163.com （ORCID： 0000-0002-1183-0283）

摘要

摘要: 在肝脏中髓系细胞触发受体2（TREM2）表达于常驻非实质细胞，参与肝脏炎症、免疫调控等病理过程。近年来，TREM2在急慢性肝病研究领域中受到关注，且越来越多的研究表明TREM2是治疗急慢性肝病的潜在靶点，然而其在急慢性肝病中的作用机制缺乏系统性的总结。本文综述了TREM2在急慢性肝病中调控作用的最新研究进展，以期为临床防治急慢性肝病提供新思路。
- 髓系细胞触发受体2 /
- 肝疾病 /
- 病理过程
Abstract: Triggering receptor expressed on myeloid cells 2 （TREM2） is expressed in resident non-parenchymal cells （NPCs） and is involved in various pathological processes including liver inflammation and immunoregulation. In recent years， TREM2 has attracted attention in the field of acute and chronic liver diseases， and more and more studies have shown that TREM2 is a potential target for the treatment of acute and chronic liver diseases； however， there is a lack of systematic summary for the mechanism of action of TREM2 in acute and chronic liver diseases. Therefore， this article reviews the latest research advances in the regulatory role of TREM2 in acute and chronic liver diseases， in order to provide new ideas for the clinical prevention and treatment of acute and chronic liver diseases.
- Triggering Receptor Expressed on Myeloid Cells 2 /
- Liver Diseases /
- Pathologic Processes

HTML全文

参考文献(47)

[1]	COLONNA M. The biology of TREM receptors[J]. Nat Rev Immunol, 2023, 23( 9): 580- 594. DOI: 10.1038/s41577-023-00837-1.
[2]	ULLAND TK, SONG WM, HUANG SC, et al. TREM2 maintains microglial metabolic fitness in Alzheimer’s disease[J]. Cell, 2017, 170( 4): 649- 663. e 13. DOI: 10.1016/j.cell.2017.07.023.
[3]	SUN HF, FENG JG, TANG LL. Function of TREM1 and TREM2 in liver-related diseases[J]. Cells, 2020, 9( 12): 2626. DOI: 10.3390/cells9122626.
[4]	HENDRIKX T, PORSCH F, KISS MG, et al. Soluble TREM2 levels reflect the recruitment and expansion of TREM2⁺ macrophages that localize to fibrotic areas and limit NASH[J]. J Hepatol, 2022, 77( 5): 1373- 1385. DOI: 10.1016/j.jhep.2022.06.004.
[5]	INDIRA CHANDRAN V, WERNBERG CW, LAURIDSEN MM, et al. Circulating TREM2 as a noninvasive diagnostic biomarker for NASH in patients with elevated liver stiffness[J]. Hepatology, 2023, 77( 2): 558- 572. DOI: 10.1002/hep.32620.
[6]	PERUGORRIA MJ, ESPARZA-BAQUER A, OAKLEY F, et al. Non-parenchymal TREM-2 protects the liver from immune-mediated hepatocellular damage[J]. Gut, 2019, 68( 3): 533- 546. DOI: 10.1136/gutjnl-2017-314107.
[7]	XIONG XL, KUANG H, ANSARI S, et al. Landscape of intercellular crosstalk in healthy and NASH liver revealed by single-cell secretome gene analysis[J]. Mol Cell, 2019, 75( 3): 644- 660. e 5. DOI: 10.1016/j.molcel.2019.07.028.
[8]	GOVAERE O, COCKELL S, TINIAKOS D, et al. Transcriptomic profiling across the nonalcoholic fatty liver disease spectrum reveals gene signatures for steatohepatitis and fibrosis[J]. Sci Transl Med, 2020, 12( 572): eaba4448. DOI: 10.1126/scitranslmed.aba4448.
[9]	ESPARZA-BAQUER A, LABIANO I, SHARIF O, et al. TREM-2 defends the liver against hepatocellular carcinoma through multifactorial protective mechanisms[J]. Gut, 2021, 70( 7): 1345- 1361. DOI: 10.1136/gutjnl-2019-319227.
[10]	MOLGORA M, ESAULOVA E, VERMI W, et al. TREM2 modulation remodels the tumor myeloid landscape enhancing anti-PD-1 immunotherapy[J]. Cell, 2020, 182( 4): 886- 900. e 17. DOI: 10.1016/j.cell.2020.07.013.
[11]	HAN S, LI XD, XIA N, et al. Myeloid Trem2 dynamically regulates the induction and resolution of hepatic ischemia-reperfusion injury inflammation[J]. Int J Mol Sci, 2023, 24( 7): 6348. DOI: 10.3390/ijms24076348.
[12]	LANIER LL, CORLISS BC, WU J, et al. Immunoreceptor DAP12 bearing a tyrosine-based activation motif is involved in activating NK cells[J]. Nature, 1998, 391( 6668): 703- 707. DOI: 10.1038/35642.
[13]	ULLAND TK, COLONNA M. TREM2—a key player in microglial biology and Alzheimer disease[J]. Nat Rev Neurol, 2018, 14: 667- 675. DOI: 10.1038/s41582-018-0072-1.
[14]	PENG QS, MALHOTRA S, TORCHIA JA, et al. TREM2- and DAP12-dependent activation of PI3K requires DAP10 and is inhibited by SHIP1[J]. Sci Signal, 2010, 3( 122): ra38. DOI: 10.1126/scisignal.2000500.
[15]	KOBER DL, BRETT TJ. TREM2-ligand interactions in health and disease[J]. J Mol Biol, 2017, 429( 11): 1607- 1629. DOI: 10.1016/j.jmb.2017.04.004.
[16]	HAMERMAN JA, JARJOURA JR, HUMPHREY MB, et al. Cutting edge: Inhibition of TLR and FcR responses in macrophages by triggering receptor expressed on myeloid cells(TREM)-2 and DAP12[J]. J Immunol, 2006, 177( 4): 2051- 2055. DOI: 10.4049/jimmunol.177.4.2051.
[17]	PALONEVA J, MANDELIN J, KIIALAINEN A, et al. DAP12/TREM2 deficiency results in impaired osteoclast differentiation and osteoporotic features[J]. J Exp Med, 2003, 198( 4): 669- 675. DOI: 10.1084/jem.20030027.
[18]	BHARADWAJ S, GROZA Y, MIERZWICKA JM, et al. Current understanding on TREM-2 molecular biology and physiopathological functions[J]. Int Immunopharmacol, 2024, 134: 112042. DOI: 10.1016/j.intimp.2024.112042.
[19]	KHANTAKOVA D, BRIOSCHI S, MOLGORA M. Exploring the impact of TREM2 in tumor-associated macrophages[J]. Vaccines(Basel), 2022, 10( 6): 943. DOI: 10.3390/vaccines10060943.
[20]	FEUERBACH D, SCHINDLER P, BARSKE C, et al. ADAM17 is the main sheddase for the generation of human triggering receptor expressed in myeloid cells(hTREM2) ectodomain and cleaves TREM2 after Histidine 157[J]. Neurosci Lett, 2017, 660: 109- 114. DOI: 10.1016/j.neulet.2017.09.034.
[21]	NI M, ZHANG J, SOSA R, et al. T-cell immunoglobulin and mucin domain-containing protein-4 is critical for kupffer cell homeostatic function in the activation and resolution of liver ischemia reperfusion injury[J]. Hepatology, 2021, 74( 4): 2118- 2132. DOI: 10.1002/hep.31906.
[22]	POWELL EE, WONG VW, RINELLA M. Non-alcoholic fatty liver disease[J]. Lancet, 2021, 397( 10290): 2212- 2224. DOI: 10.1016/S0140-6736(20)32511-3.
[23]	LEUNG PB, DAVIS AM, KUMAR S. Diagnosis and management of nonalcoholic fatty liver disease[J]. JAMA, 2023, 330( 17): 1687- 1688. DOI: 10.1001/jama.2023.17935.
[24]	LIEBOLD I, MEYER S, HEINE M, et al. TREM2 regulates the removal of apoptotic cells and inflammatory processes during the progression of NAFLD[J]. Cells, 2023, 12( 3): 341. DOI: 10.3390/cells12030341.
[25]	DAWS MR, SULLAM PM, NIEMI EC, et al. Pattern recognition by TREM-2: Binding of anionic ligands[J]. J Immunol, 2003, 171( 2): 594- 599. DOI: 10.4049/jimmunol.171.2.594.
[26]	TURNBULL IR, GILFILLAN S, CELLA M, et al. Cutting edge: TREM-2 attenuates macrophage activation[J]. J Immunol, 2006, 177( 6): 3520- 3524. DOI: 10.4049/jimmunol.177.6.3520.
[27]	WANG XC, HE QF, ZHOU CL, et al. Prolonged hypernutrition impairs TREM2-dependent efferocytosis to license chronic liver inflammation and NASH development[J]. Immunity, 2023, 56( 1): 58- 77. e 11. DOI: 10.1016/j.immuni.2022.11.013.
[28]	HOU JC, ZHANG J, CUI P, et al. TREM2 sustains macrophage-hepatocyte metabolic coordination in nonalcoholic fatty liver disease and sepsis[J]. J Clin Invest, 2021, 131( 4): e135197. DOI: 10.1172/JCI135197.
[29]	ZHOU LK, QIU XX, MENG ZY, et al. Hepatic danger signaling triggers TREM2⁺ macrophage induction and drives steatohepatitis via MS4A7-dependent inflammasome activation[J]. Sci Transl Med, 2024, 16( 738): eadk1866. DOI: 10.1126/scitranslmed.adk1866.
[30]	WOOLBRIGHT BL, JAESCHKE H. Inflammation and cell death during cholestasis: The evolving role of bile acids[J]. Gene Expr, 2019, 19( 3): 215- 228. DOI: 10.3727/105221619X15614873062730.
[31]	de VRIES E, BEUERS U. Management of cholestatic disease in 2017[J]. Liver Int, 2017, 37( Suppl 1): 123- 129. DOI: 10.1111/liv.13306.
[32]	LABIANO I, AGIRRE-LIZASO A, OLAIZOLA P, et al. TREM-2 plays a protective role in cholestasis by acting as a negative regulator of inflammation[J]. J Hepatol, 2022, 77( 4): 991- 1004. DOI: 10.1016/j.jhep.2022.05.044.
[33]	IREDALE JP. Models of liver fibrosis: Exploring the dynamic nature of inflammation and repair in a solid organ[J]. J Clin Invest, 2007, 117( 3): 539- 548. DOI: 10.1172/JCI30542.
[34]	KISSELEVA T, BRENNER D. Molecular and cellular mechanisms of liver fibrosis and its regression[J]. Nat Rev Gastroenterol Hepatol, 2021, 18( 3): 151- 166. DOI: 10.1038/s41575-020-00372-7.
[35]	RAMACHANDRAN P, DOBIE R, WILSON-KANAMORI JR, et al. Resolving the fibrotic niche of human liver cirrhosis at single-cell level[J]. Nature, 2019, 575( 7783): 512- 518. DOI: 10.1038/s41586-019-1631-3.
[36]	ZHU DD, HUANG M, SHEN P, et al. TREM2 expression promotes liver and peritoneal M2 macrophage polarization in mice infected with Schistosoma japonicum[J]. J Cell Mol Med, 2023, 27( 15): 2261- 2269. DOI: 10.1111/jcmm.17842.
[37]	YE ZH, HUANG SG, ZHANG YX, et al. Galectins, eosinophiles, and macrophages may contribute to Schistosoma japonicum egg-induced immunopathology in a mouse model[J]. Front Immunol, 2020, 11: 146. DOI: 10.3389/fimmu.2020.00146.
[38]	SHAN S, CHAO S, LIU Z, et al. TREM2 protects against inflammation by regulating the release of mito-DAMPs from hepatocytes during liver fibrosis[J]. Free Radic Biol Med, 2024, 220: 154- 165. DOI: 10.1016/j.freeradbiomed.2024.05.004.
[39]	MANTOVANI A, MARCHESI F, MALESCI A, et al. Tumour-associated macrophages as treatment targets in oncology[J]. Nat Rev Clin Oncol, 2017, 14( 7): 399- 416. DOI: 10.1038/nrclinonc.2016.217.
[40]	DENARDO DG, RUFFELL B. Macrophages as regulators of tumour immunity and immunotherapy[J]. Nat Rev Immunol, 2019, 19( 6): 369- 382. DOI: 10.1038/s41577-019-0127-6.
[41]	CASSETTA L, POLLARD JW. Targeting macrophages: Therapeutic approaches in cancer[J]. Nat Rev Drug Discov, 2018, 17( 12): 887- 904. DOI: 10.1038/nrd.2018.169.
[42]	WANG QY, ZHENG K, TAN D, et al. TREM2 knockdown improves the therapeutic effect of PD-1 blockade in hepatocellular carcinoma[J]. Biochem Biophys Res Commun, 2022, 636( Pt 1): 140- 146. DOI: 10.1016/j.bbrc.2022.10.079.
[43]	ZHOU LS, WANG ML, GUO HR, et al. Integrated analysis highlights the immunosuppressive role of TREM2⁺ macrophages in hepatocellular carcinoma[J]. Front Immunol, 2022, 13: 848367. DOI: 10.3389/fimmu.2022.848367.
[44]	VOGEL A, MEYER T, SAPISOCHIN G, et al. Hepatocellular carcinoma[J]. Lancet, 2022, 400( 10360): 1345- 1362. DOI: 10.1016/S0140-6736(22)01200-4.
[45]	PALMER DH, MALAGARI K, KULIK LM. Role of locoregional therapies in the wake of systemic therapy[J]. J Hepatol, 2020, 72( 2): 277- 287. DOI: 10.1016/j.jhep.2019.09.023.
[46]	SUN YF, WU L, ZHONG Y, et al. Single-cell landscape of the ecosystem in early-relapse hepatocellular carcinoma[J]. Cell, 2021, 184( 2): 404- 421. e 16. DOI: 10.1016/j.cell.2020.11.041.
[47]	TAN JZ, FAN WZ, LIU T, et al. TREM2⁺ macrophages suppress CD8⁺ T-cell infiltration after transarterial chemoembolisation in hepatocellular carcinoma[J]. J Hepatol, 2023, 79( 1): 126- 140. DOI: 10.1016/j.jhep.2023.02.032.